Intratumoral delivery of engineered recombinant modified vaccinia virus Ankara expressing Flt3L and OX40L generates potent antitumor immunity through activating the cGAS/STING pathway and depleting tumor-infiltrating regulatory T cells
Ning Yang(Memorial Sloan Kettering Cancer Center), Liang Deng(Memorial Sloan Kettering Cancer Center), Shuaitong Liu(Memorial Sloan Kettering Cancer Center), Charles M. Rice(Rockefeller University), Anthony Rossi(Memorial Sloan Kettering Cancer Center), Jenny Xiang(Cornell University), Gregory Mazo(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Adrian Y. Tan(NewYork–Presbyterian Hospital), Joseph M. Luna(Rockefeller University), Yi Wang(University of Science and Technology of China), Tuo Zhang(Cornell University), Wei Yan(Q Therapeutics (United States)), Taha Merghoub(Cornell University), John Choi(Q Therapeutics (United States)), Jiahu Wang
Cited by 1
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k